BioSpace News Archive

Nephron Pharmaceuticals Corporation has joined forces with the University of South Carolina’s College of Engineering and Computing and the College of Pharmacy to design and implement an automation process that significantly boosts production of pre-filled medication, reducing the physical burden on workers and increasing patient safety.

Beyond Next Ventures Inc. and DENSO Corporation today announced that they have established OPExPARK Inc., a carve-out*1 to develop the businesses utilizing OPeLiNK®*2. OPExPARK will develop and sell systems that integrate information from surgery equipment, produce educational content for physicians, and offer distribution services.

The Foundation for Sarcoidosis Research (FSR) is teaming up with internationally-recognized physicians to host an educational conference for people affected by sarcoidosis in Boston.

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units (“RSUs”) to 15 new employees in connection with their employment with UroGen.

National Chemicals, Inc. (NCI), a Minnesota-based chemical manufacturing company owned by Murl Landman, a resident of Naples, is partnering with Venue Naples and other local Lee County companies to organize relief and donations for the Bahamas recently devastated by Hurricane Dorian.

Health Canada is advising Canadians who use vaping products to monitor themselves for symptoms of pulmonary illness (e.g., cough, shortness of breath, chest pain) and to seek medical attention promptly if they have concerns about their health.

Audentes Therapeutics, Inc. announced it has granted equity awards that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to seventeen individuals hired by Audentes from July 16 through August 31, 2019.

The U.S. Food and Drug Administration today issued the following Consumer Update:

Windtree Therapeutics, Inc. (OTCQB: WINT), today announced the full publication of previously described results of a lung deposition study conducted in non-human primates (NHPs) that demonstrated the Company’s proprietary aerosol delivery system (ADS) is capable of delivering aerosolized lucinactant (the Company’s lyophilized KL4 surfactant) throughout all regions of the lung.

In a matter of days, every health center in America stands to lose more than 70% of their federal grant funding without Congress extending the funding by September 30.